-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ulcerative colitis (UC) is a lifelong inflammatory rectal or colorectal disease characterized by recurrent or persistent colon inflammation.
Ulcerative colitis (UC) is a lifelong inflammatory rectal or colorectal disease characterized by recurrent or persistent colon inflammation.
The researchers followed the French health insurance database for patients over 18 years of age who were diagnosed with UC and who had previously received or started immunosuppressive therapy from January 1, 2009 to December 31, 2018 , and then used the marginal structure Cox ratio The risk model assesses the risk of CRC in patients receiving anti-TNF therapy, and analyzes secondary targets including primary sclerosing cholangitis and UC disease activity
Diagnostic immunity
The results of the study showed that among 32,403 UC patients, 15,542 (48.
In summary, this population-based cohort study of more than 30,000 patients is the first to specifically assess the impact of anti-TNF drugs on the risk of colon cancer in UC patients
In summary, this population-based cohort study of more than 30,000 patients is the first to specifically assess the impact of anti-TNF drugs on the risk of colon cancer in UC patients
Maeva Charkaoui.
Impact of anti-tumor necrosis factor agents on the risk of colorectal cancer in patients with ulcerative colitis: nationwide French cohort study.
Leave a message here